AI development of self-supervised fluency therapy for people who stammer: micro-randomisation haptic feedback research study

高达3%的人口口吃(英国踩踏协会，2019年)。这种情况可能会有令人痛苦的症状，深刻影响社会和职业互动，并可能定义那些Stammer(PWS)患者的生活选择：60%的PWS患有社交焦虑障碍(SAD)(McAllister等人，2017年)。即使目前还不可能治愈口吃，但一旦在成年后建立起来，就存在一系列练习，当掌握这些练习时，可以帮助PWS获得与不结巴的人类似的流利水平。对许多PWS来说，最大的问题不是学习技术本身，而是将这些练习变成习惯，因为这需要耐心和对持续练习的支持。我们相信，技术可以帮助这一努力：BeneTalk是第一个可穿戴设备，它帮助Stammer(PWS)患者建立和保持在最初的治疗过程中学到的流利性增强技术。这是通过一种新型的数字技术应用来实现的，该技术能够在实时反馈和绩效历史跟踪的支持下，首次实施临床外治疗。作为一种以可穿戴设备为核心的治疗方法，BeneTalk作为一种新产品应运而生，它与一种创新的数字服务相关联，帮助PWS控制自己的治疗。BeneTalk为一个古老的治疗问题提供了期待已久的解决方案，有可能展示出在疗效、速度和成本方面的重大阶梯变化。BeneTalk充当PWS的虚拟教练；作为言语和语言治疗师的治疗工具；以及科学仪器。我们已经为BeneTalk背后的创新技术申请了专利，因为这是第一次。有关BeneTalk的详细信息可在[www.benetalk.com][0]上找到。该项目将使用科学和技术证据验证BeneTalk，使英国印章协会(BSA)能够认可BeneTalk疗法是有效的，与PWS的密切联系将帮助我们更好地了解商业需求。因此，BeneTalk将在筹集私人资金和将产品商业化方面处于更有利的地位。该项目将使雷丁大学(UOR)能够公布第一个走出临床的实时反馈辅助流利疗法的结果。出版物将基于前所未有的数量和种类的数据，这些数据可能会改变未来流利性研究的方向。[0]：http://www.benetalk.com/

Up to 3% of the population stammers (British Stammering Association, 2019). This condition can have distressing symptoms that deeply affect social and professional interactions and can define the life choices of those People Who Stammer (PWS): 60% of PWS suffer from Social Anxiety Disorder (SAD) (McAllister et al., 2017). Even if it is not currently possible to cure stammering, once it is established in adulthood, there exist a series of practices that, when mastered, help PWS to gain fluency levels similar to those of people who don't stammer.For many PWS, the largest problem is not learning the techniques themselves, but turning these practices into habits, as this requires patience and support with ongoing practice. We believe that technology can help in this endeavour: BeneTalk is the first wearable device, which helps People Who Stammer (PWS) to establish and maintain fluency enhancing techniques learned in the initial therapy process. This is achieved through a novel application of digital technologies that enable the first implementation of an out-of-the-clinic therapy, supported by real-time feedback and performance history tracking. As a treatment centred on a wearable device, BeneTalk emerges as a new product linked to an innovative digital service that helps PWS to be in control of their own therapy. BeneTalk delivers a long-awaited solution to an old therapeutic problem with the potential to demonstrate significant step-changes in efficacy, speed and cost. BeneTalk acts as a virtual coach for PWS; as a therapeutic tool for speech and language therapists (SLTs); and a scientific instrument. We have filed a patent for the innovative technology behind BeneTalk as it is the first of its kind. Detailed information about BeneTalk can be found on [www.benetalk.com][0].This project will validate BeneTalk using scientific and technical evidence, enabling the British Stammering Association (BSA) to endorse BeneTalk therapy as valid and close contact with PWS will help us to better understand commercial requirements. Consequently, BeneTalk will be in a stronger position to raise private funding and commercialise the product.This project will enable the University of Reading (UoR) to publish the results of the first out-of-the-clinic real-time feedback assisted fluency therapy. Publications will be based on an unprecedented quantity and variety of data that may redirect future fluency research.[0]: http://www.benetalk.com/